373 related articles for article (PubMed ID: 31177102)
1. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
5. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
6. Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma.
Lyu C; Li W; Liu S; Gao S; Zhang H; Hao L; Yu H; Wei W; Song J; Yang Y; Wang C; Zhang Z; Wang N
Future Oncol; 2018 Sep; 14(21):2207-2221. PubMed ID: 29726696
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Therapies for Renal Cell Carcinoma.
Liu M; Wu H; Shangguan D; Jiang Y; Li X; Liu S; Zhou B; Yin T; Gong Z
Protein Pept Lett; 2018; 25(6):534-547. PubMed ID: 29848257
[TBL] [Abstract][Full Text] [Related]
8. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
9. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
10. A review of checkpoint inhibitors in the management of renal cell carcinoma.
Hanna KS
J Oncol Pharm Pract; 2020 Mar; 26(2):445-458. PubMed ID: 31631812
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
Guida M; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
14. Designing novel immunocombinations in metastatic renal cell carcinoma.
Santoni M; Massari F; Aurilio G; Mollica V; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Nolé F; Montironi R
Immunotherapy; 2020 Dec; 12(17):1257-1268. PubMed ID: 32998603
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review.
Bracarda S; Porta C; Sabbatini R; Rivoltini L
Crit Rev Oncol Hematol; 2019 Jul; 139():149-157. PubMed ID: 30424938
[TBL] [Abstract][Full Text] [Related]
16. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
Grünwald V
Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
[TBL] [Abstract][Full Text] [Related]
17. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy.
Dutcher JP; Flippot R; Fallah J; Escudier B
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32243201
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
Gill D; Hahn AW; Sonpavde G; Agarwal N
Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
